


Applicants : Anthony A. Sauvé and Vern L. Schramm
Serial No. : 10/038,760
Filed : January 4, 2002
Art Unit : 1614
Page 2

Amendment

IN THE CLAIMS ✓

Please amend the claims as follows, which add new claims 30-37.

1 (original): A compound represented by the formula:



wherein A is a nitrogen-, oxygen-, or sulfur-linked aryl, alkyl, cyclic, or heterocyclic group; B is hydrogen, or a halogen, amino, or thiol group; C is hydrogen, or a halogen, amino, or thiol group; and D is a primary alcohol, a hydrogen, or an oxygen, nitrogen, carbon, or sulfur linked to phosphate, a phosphoryl group, a pyrophosphoryl group, or adenosine monophosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted phosphodiester bridge, or to adenosine diphosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted pyrophosphodiester bridge.

2 (original): The compound of claim 1, wherein A is an N-linked aryl or heterocyclic group.

Applicants : Anthony A. Sauvé and Vern L. Schramm
Serial No. : 10/038,760
Filed : January 4, 2002
Art Unit : 1614
Page 3

3 (original): The compound of claim 2, wherein A is a nicotinamide group, a pyridyl group, a substituted pyridyl group, a pyrimidyl group, or a substituted pyrimidyl group.

4 (original): The compound of claim 3, which is a nicotinamide 2'-deoxyriboside.

5 (original): The compound of claim 3, which is β -1'-nicotinamide-2'-deoxyribose, β -D-1'-nicotinamide-2'-deoxyribofuranoside, β -1'-pyridyl-2'-deoxyribose, or 5'-phospho-1'-pyridyl-deoxyribose.

6 (original): The compound of claim 1, wherein A is an O-linked aryl or heterocyclic group having the formula -O-Y, wherein Y is an aryl or heterocyclic group.

7 (original): The compound of claim 6, wherein the aryl or heterocyclic group is a phenyl group, a substituted phenyl group, a pyridyl group, a substituted pyridyl group, or a pyrimidyl group.

8 (original): The compound of claim 1, wherein A is an S-linked aryl or heterocyclic group having the formula -S-Y, wherein Y is an aryl or heterocyclic group.

9 (original): The compound of claim 8, wherein the aryl or heterocyclic group is a phenyl group, a substituted phenyl group, a pyridyl group, a substituted pyridyl group, or a pyrimidyl group.

Applicants : Anthony A. Sauvé and Vern L. Schramm
Serial No. : 10/038,760
Filed : January 4, 2002
Art Unit : 1614
Page 4

10 (original): The compound of claim 1, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen.

11 (original): The compound of claim 2, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen.

12 (original): The compound of claim 6, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen.

13 (original): The compound of claim 8, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen.

14 (original): The compound of claim 1, wherein D is a primary alcohol or hydrogen.

15 (original): The compound of claim 2, wherein D is a primary alcohol or hydrogen.

16 (original): The compound of claim 6, wherein D is a primary alcohol or hydrogen.

17 (original): The compound of claim 8, wherein D is a primary alcohol or hydrogen.

Applicants : Anthony A. Sauvé and Vern L. Schramm
Serial No. : 10/038,760
Filed : January 4, 2002
Art Unit : 1614
Page 5

18 (original): A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically-acceptable carrier.

19 (original): A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically-acceptable carrier.

20 (original): A pharmaceutical composition comprising the compound of claim 6 and a pharmaceutically-acceptable carrier.

21 (original): A pharmaceutical composition comprising the compound of claim 8 and a pharmaceutically-acceptable carrier.

22-29 (cancelled)

30 (new): The compound of claim 3, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen.

31 (new): The compound of claim 4, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen.

32 (new): The compound of claim 5, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen.

33 (new): The compound of claim 3, wherein D is a primary alcohol or hydrogen.

Applicants : Anthony A. Sauvé and Vern L. Schramm

Serial No. : 10/038,760

Filed : January 4, 2002

Art Unit : 1614

Page 6

34 (new): The compound of claim 4, wherein D is a primary alcohol or hydrogen.

35 (new): The compound of claim 5, wherein D is a primary alcohol or hydrogen.

36 (new): A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutically-acceptable carrier.

37 (new): A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically-acceptable carrier.

Election/Restriction

The Office Action dated May 6, 2003 requires an election among the claimed deoxyriboside compounds wherein A in the formula is one of the following species: nitrogen linked aryl, cyclic; nitrogen linked alkyl; nitrogen linked heterocyclic group; oxygen linked aryl, cyclic; oxygen linked alkyl; oxygen linked heterocyclic group; sulfur linked aryl, cyclic; sulfur linked alkyl; and sulfur linked heterocyclic group. Applicant elects the species where A is a nitrogen linked heterocyclic group. The claims encompassing this group are 1, 2, 3, 4, 5, 10, 11, 14, 15, 18, 19, 30, 31, 32, 33, 34, 35, 36 and 37.

Conclusion

With this Amendment and Reply, applicants add claims 30-37 to more particularly point out and distinctly claim the invention, and elect the species where A in the formula is a nitrogen linked heterocyclic group.


Applicants : Anthony A. Sauvé and Vern L. Schramm
Serial No. : 10/038,760
Filed : January 4, 2002
Art Unit : 1614
Page 7

It is believed that no fee is required with this Amendment and Reply. Since 29 claims have already been paid for, the addition of new claims 30-37, bringing the total currently pending claims to 29, should not require the payment of an additional fee. However, if there is an unexpected fee required to maintain the pendency of this application, authorization is hereby given to charge that fee, or credit any over-payment, to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN
Attorneys for Applicants
90 Park Avenue
New York, New York 10016
(212) 697-5995

Dated: June 4, 2003
New York, New York

By 
Elie H. Gendloff
Reg. No. 44,704